Your Article Summary
See Latest ArticlesAbsenteeism and health-benefit costs among employees with MS
Current Medical Research and Opinion, 06/25/09
Brook RA et al. - Patients treated with 'A' reported significantly lower SL costs, SL days, and STD costs than patients treated with 'C', suggestive of greater real world benefits with 'A'. Despite small sample sizes and the retrospective nature, the study provides interesting insights into the use of DMTs in MS. The study also revealed important areas of future research, specifically the need for development of methods to determine which MS patient groups respond best to which DMT treatments.
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09
Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets, 12/10/09
An Open Pilot Study Assessing the Benefits of Quetiapine for the Prevention of Migraine Refractory to the Combination of Atenolol, Nortriptyline, and Flunarizine
Pain Medicine, 12/10/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Economic consequences of ACS-related rehospitalizations in the US
Current Medical Research and Opinion, 12/10/09
Out-of-pocket Prices of Opioid Analgesics in the United States, 1999–2004
Pain Medicine, 12/10/09
The Impact of Disposables on Project Economics in a New Antibody Plant
BioPharm, 12/09/09